nach oben

Die Onkologie

Erschienen in:

01.01.2005 | Leitthema

Chirurgie der Schilddrüsenkarzinome

Sollten nach Einführung der neuen TNM-Klassifikation die chirurgischen Leitlinien geändert werden?

verfasst von: Prof. Dr. H. Dralle, A. Machens, M. Brauckhoff, J. Ukkat, C. Sekulla, P. Nguyen-Thanh, K. Lorenz, O. Gimm

Erschienen in: Die Onkologie | Ausgabe 1/2005

Einloggen, um Zugang zu erhalten

Zusammenfassung

Durch Änderung der TNM-Klassifikation (2002) hat sich erneut eine intensive Diskussion über die Leitlinien der Chirurgie der Schilddrüsenkarzinome (2000), v. a. in Bezug auf die Frühformen des differenzierten Karzinoms (DTC) entwickelt. Da keine ausreichenden Literaturdaten vorliegen, die eine Definitionsänderung der bisherigen Hauptkategorien der TNM-Klassifikation begründen könnten, die TNM-Klassifikationen von 2002 und 1997 nicht kompatibel sind und die fortgeschrittenen Tumoren (pT3/4) nur in Verbindung mit dem klinischen Befund definiert werden können, stellt die neue TNM-Klassifikation keine geeignete Grundlage zur Stadieneinteilung der Schilddrüsenkarzinome dar. Unabhängig von der neuen TNM-Klassifikation ergibt sich Änderungsbedarf bei den chirurgischen Leitlinien besonders bezüglich der prophylaktischen zentralen Lymphadenektomie beim DTC, für die sich aufgrund vorliegender Daten keine Evidenz nachweisen lässt. Beim hereditären medullären Karzinom ist bei Genträgern ohne klinisch manifesten Tumor wegen der Genotyp-Phänotyp-Korrelation ein risikoadaptiertes Vorgehen hinsichtlich Zeitpunkt und Ausmaß der prophylaktischen Operation zu empfehlen. Bei resektablen, wenig differenzierten und undifferenzierten Karzinomen nimmt die Chirurgie innerhalb eines multimodalen Therapiekonzepts eine wichtige Stellung ein.

Akslen LA, Haldorsen T, Thoresen S, Glattre E (1991) Survival and causes of death in thyroid cancer: a population-based study of 2479 cases from Norway. Cancer Research 51:1234–1241

Brandi MI, Gagel RE, Angeli A et al. (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658–5671

Brauckhoff M, Gimm O, Brauckhoff K, Ukkat J, Thomusch O, Dralle H (2001) Calcitonin kinetics in the early postoperative period of medullary thyroid carcinoma. Langenbeck’s Arch Surg 386:434–439

Brennan MD, Bergstralh EJ, van Heerden JA, McConahey WM (1991) Follicular thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 66:11–22PubMed

British guidelines for the management of thyroid cancer in adults (2002) British Thyroid Association and Royal College of Physicians. http://www.british-thyroid-association.org

Cady B, Segdwick CE, Meissner WA, Bookwalter JR et al. (1976) Changing clinical, pathologic, therapeutic, and survival patterns in differentiated thyroid carcinoma. Ann Surg 184:541–553PubMed

Cady B, Rossi R (1988) An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104:947–953PubMed

Cady B (1998) Presidential address: beyond risk groups-a new look at differentiated thyroid cancer. Surgery 124:947–957PubMed

Chao TC, Lin JD, Chen MF (2004) Insular carcinoma: infrequent subtype of thyroid cancer with aggressive clinical course. World J Surg 28:393–396PubMed

10.

Cohen R, Campos JM, Salaün C, Heshmati HM, Kraimps JL, Proye C, Sarfati E, Henry JF, Niccoli-Sire P, Modigliani E (2000) Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. J Clin Endocrinol Metab 80:919–922CrossRef

11.

DeGroot LJ, Kaplan EL, McCormick M, Straus FH (1990) Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71:414–424

12.

DeGroot LJ, Kaplan EL, Shukla MS, Salti G, Straus FH (1995) Morbitidy and mortality in follicular thyroid cancer. J Clin Endocrinol Metab 80:2946–2953

13.

Dralle H, Scheumann GFW, Hundeshagen H, Massmann J, Pichlmayr R (1992) Die transsternale zervikomediastinale Primärtumorresektion und Lymphadenektomie beim Schilddrüsenkarzinom. Langenbecks Arch Chir 377:34–44

14.

Dralle H, Scheumann GFW, Meyer HJ, Laubert A, Pichlmayer R (1992) Cervicale Eingriffe an der Luft- und Speiseröhre beim organüberschreitenden Schilddrüsencarcinom. Chirurg 63:282–290PubMed

15.

Dralle H, Scheumann GFW (1993) Defektrekonstruktion an den cervicalen Viszeralorganen nach Resektion organüberschreitender Schilddrüsencarcinome. Langenbeck’s Arch Chir Suppl 486–489

16.

Dralle H, Scheumann GFW, Proye C, Bacourt F, Frilling A, Limbert F, Gheri G, Henry JF, Berner M, Niederle B, Vasen HFA (1995) The value of lymph node dissection in hereditary medullary thyroid carcinoma—a retrospective European multicenter study. J Intern M 238:357–361

17.

Dralle H, Gimm O (1996) Lymphadenektomie beim Schilddrüsenkarzinom. Chirurg 67:788–806PubMed

18.

Dralle H, Gimm O, Simon D, Frank-Raue K, Görtz G, Niederle B, Wahl RA, Koch B, Walgenbach S, Hampel R, Ritter MM, Spelsberg F, Heiss A, Hinze R, Höppner W (1998) Prophylactic thyreoidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma—The German and Austrian experience. World J Surg 22:744–751PubMed

19.

Dralle H, Sekulla C, Haerting J, Timmermann W, Neumann HJ, Kruse E, Grond S, Mühling HP, Richter C, Voß J, Thomusch O, Lippert H, Gastinger I, Brauckhoff M, Gimm O (2004) Risk factors of recurrent laryngeal nerve (RLN) paralysis and functional outcome after RLN monitoring in thyroid surgery. Surgery (in press)

20.

Dralle H, Brauckhoff M, Machens A, Gimm O. Surgical management of advanced thyroid cancer invading the aerodigestive tract. In: Clark OH, Duh QY (eds) Textbook of Endocrine Surgery, 2^nd en (in press)

21.

Emerick GT, Duh QY, Siperstein AE, Burrow GN, Clark OH (1993) Diagnosis, treatment, and outcome of follicular thyroid carcinoma. Cancer 72:3281–3295

22.

Esnaola NF, Cantor SB, Sherman SI, Lee JE, Evans DB (2001) Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis. Surgery 130:921–930CrossRefPubMed

23.

Gilliland FD, Hunt WC, Morris DM, Key CR (1997) Prognostic factors for thyroid carcinoma. A population-based study 15.698 cases from the surveillance, epidemiology and end results (SEER) program 1973–1991. Cancer 79:564–573PubMed

24.

Gimm O, Dralle H (1997) Reoperation in metastasizing medullary thyroid carcinoma: is a tumorstage oriented approach justified? Surgery 122:1124–1131PubMed

25.

Gimm O, Ukkat J, Dralle H (1998) Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg 22:562–568PubMed

26.

Hannequin P, Liehn JC, Delisle MJ (1986) Multivariate analysis of survival in thyroid cancer. Pitfalls of applying the results of published studies to another population. Cancer 58:1749–1755PubMed

27.

Hay ID, Grant CS, Taylor WF, McConahey WM (1987) Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102:1088–1095PubMed

28.

Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS (1993) Prediting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050–1058PubMed

29.

Hay ID, Grant CS, Bergstralh EJ, Thompson GB, van Heerden JA, Goellner JR (1998) Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma ? Surgery 124:958–966CrossRefPubMed

30.

Hermanek P, Henson DE, Hutter RVP, Sobin LH (1993) TNM Supplement 1993, Springer, Berlin, pp 21–25

31.

Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1998) A national cancer data base report on 53.856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer 83:2638–2648CrossRefPubMed

32.

Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der Deutschen Gesellschaft für Chirurgie (2000) Maligne Schilddrüsentumoren. AWMF online 2000. http://www.uni-duesseldorf.de

33.

Kaluber J, Robra BP, Schellschmidt H (2003) Krankenhausreport 2003. Wissenschaftliches Institut der AOK, Schattauer

34.

Karges W, Dralle H, Raue F, Mann K, Reiners C, Grussendorf M, Hüfner M, Niederle B, Brabant G (2004) German Society for Endocrinology (DGE)—Thyroid Section. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 112:52–58PubMed

35.

Kebebew E, Duh QY, Clark OH (2000) Total thyreoidectomy or thyroid lobectomy in patients with low-risk differentiated thyroid cancer: surgical decision analysis of a controversy using a mathematical model. World J Surg 24:1295–1202PubMed

36.

Langsteger W, Költringer P, Wolf G, Dominik K, Buchinger W, Binter G, Lax S, Eber O (1993) The impact of geographical, clinical, dietary and radiation-induced features in epidemiology of thyroid cancer. Eur J Cancer 29A: 1547–1553PubMed

37.

Leitlinien der Therapie maligner Schilddrüsentumoren (1996) Erarbeitet von den Arbeitsgemeinschaften der Deutschen Krebsgesellschaft. Beilage zu den Mitteilungen der deutschen Gesellschaft für Chirurgie. Demeter, Balingen, Heft 3

38.

Lerch H, Schober O, Kuwert T, Saur HB (1997) Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Oncol 15:2067–2075PubMed

39.

Lindahl F (1975) Papillary thyroid carcinoma In Denmark 1943–1968. Treatment and survival. Acta Chir Surg 141:504

40.

Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PPB (1997) Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 82:3553–3562

41.

Machens A, Gimm O, Ukkat J, Hinze R, Schneyer U, Dralle H (2000) Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Cancer 88:1909–1915PubMed

42.

Machens A, Gimm O, Hinze R, Höppner W, Boehm BO, Dralle H (2001) Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: Oncological features and biochemical properties. J Clin Endocrinol Metab 86:1104–1109CrossRefPubMed

43.

Machens A, Hinze R, Lautenschläger C, Thomusch O, Dralle H (2001) Thyroid carcinoma invading the cervicoviszeral axis: routes of invasion and clinical implications. Surgery 129:23–28PubMed

44.

Machens A, Hinze R, Lautenschläger C, Thomusch O, Dunst J, Dralle H (2001) Extended surgery and early postoperative radiotherapy for undifferentiated thyroid carcinoma. Thyroid 11:373–380PubMed

45.

Machens A, Hinze R, Lautenschläger C, Dralle H (2001) Multivariate analysis of clinicopathologic parameters for the insular subtype of differentiated thyroid carcinoma. Arch Surg 136:941–944PubMed

46.

Machens A, Hinze R, Thomusch O, Dralle H (2002) Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 26:22–28PubMed

47.

Machens A, Holzhausen J, Nguyen-Thanh P, Dralle H (2003) Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations. Surgery 134:425–431CrossRefPubMed

48.

Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, Vroonhoven v TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B, Dralle H for the European Multiple Endocrine Neoplasia (EUROMEN) Study group (2003) Early malignant progression of hereditary medullary thyroid cancer. New Engl J Med 349:1517–1525PubMed

49.

Machens A, Holzhausen HJ, Lautenschläger C, Nguyen-Thanh P, Dralle H (2003) Enhancement of lymph node metastasis and distant metastasis of thyroid carcinoma: A multivariate analysis of clinical risk factors. Cancer 98:712–719PubMed

50.

Machens A, Holzhausen HJ, Dralle H (2004) Skip metastasis in thyroid cancer leaping the central lymph node compartment. Arch Surg 139:43–45PubMed

51.

Machens A, Holzhausen HJ, Dralle H (2004) Prediction of mediastinal lymph node metastasis in medullary thyroid carcinoma. Br J Surg 91:709–712PubMed

52.

Machens A, Holzhausen HJ, Lautenschläger C, Dralle H (2004) The tall-cell variant of papillary thyroid carcinoma: a multivariate analysis of clinical risk factors. Langenbeck’s Arch Surg 389:278–282

53.

Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418–428PubMed

54.

Mazzaferri EL (1999) NCCN thyroid carcinoma practice guidelines. Oncology 13:391–342

55.

McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grnat CS, Thompson GB, van Heerden JA, Goellner JR (2001) Anaplastic thyroid carcinoma : a 50-year experience at a single institution. Surgery 130:1028–1034PubMed

56.

Miyauchi A, Matsuzuka F, Kuma K, Takai S, Nakamoto K, Nakamura K, Nanjo S, Maeda M (1988) Evalution of surgical results and prediction of prognosis in patients with medullary thyroid carcinoma by analysis of serum calcitonin levels. World J Surg 12:610–615

57.

Miyauchi A, Matsuzuka F, Hirai K, Yokozawa T, Kobayashi K, Ito y, Nakano K, Kuma K, Futami H, Yamaguchi K (2002) Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations. World J Surg 26:1023–1028PubMed

58.

Modigliani E, Cohen R, Campos JM, Devolx BC, Maes B, Boneu A, Schlumberger M, Bigorgne JC, Dumontier P, Leclerc L, Corcuff B, Guilhem I and the GETC Study Group (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol 48:265–273

59.

Niccoli-Sire P, Murat A, Rohmer V, Franc S, Chabrier G, Baldet L, Maes B, Savagner F, Giraud S, Bezieau S, Kottler ML, Morange S, Conte-Devolx B (2001) Familial medullary thyroid carcinoma with noncysteine RET mutations: phenotype-genotype relationship in a large series of patients. J Clin Endocrinol Metab 86:3746–3753

60.

Nilsson O, Lindeberg J, Zedenius J, Ekman E, Tennvall J, Blomgren H, Grimelius L, Lundell G, Wallin G (1998) Anaplastic giant cell carcinoma of the thyroid cland: treatment and survival over a 25-year period. World J Surg 22:725–730PubMed

61.

Noguchi M, Kumaki T (1990) Impact of neck dissection on survival in well-differentiated thyroid cancer: a multivariante analysis of 218 cases. International Surg 75:220

62.

Noguchi S, Murakami N (1998) Papillary thyroid carcinoma: modified radical neck dissection improves prognosis. Arch Surg 133:276PubMed

63.

Passler C, Scheuba C, Prager G, Kaserer K, Flores JA, Vierhapper H, Niederle B (1999) Anaplastic (undifferentiated) thyroid carcinoma (ATC) a retrospective analysis. Langenbeck’s Arch Surg 384:284–293

64.

Robbins KT, Medina JE, Wolfe GT, Levine PA, Sessions RB, Pruet CW (1991) Standardizing neck dissection terminology. Arch Otolaryngol Head Neck Surg 117:601–605PubMed

65.

Rodriguez JM, Parrilla P, Sola J, Pinero A, Ortiz S, Soria T (1998) Insular carcinoma: an infrequent subtype of thyroid cancer. J Am Coll Surg 187:503–508PubMed

66.

Rüter A, Nishiyama R, Lennquist S (1997) Tall-cell variant of papillary thyroid cancer: disregarded entity? World J Surg 21:15–21PubMed

67.

Scheidt A, Käufer C (1992) Stellenwert der zweizeitigen Thyreoidektomie beim Schilddrüsenkarzinom. Akt Chir 27:121–125

68.

Scheumann GFW, Wegener G, Dralle H (1990) Radical surgical intervention with conventional radiation versus multimodatily therapy protocol in undifferentiated thyroid cancer. Wien Klin Wochenschr 102:271–273PubMed

69.

Scheumann GFW, Gimm O, Wegener G, Hundeshagen H, Dralle H (1994) Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 18:559PubMed

70.

Schmid KW, Wittekind C (2003) Die missglückte Klassifikation. Pathologe 24:338CrossRef

71.

Schmid KW, Sheu SY, Gorges R, Ensinger C, Totsch M (2003) Tumoren der Schilddrüse. Pathologe 24:357–372PubMed

72.

Schmutzler C, Köhrle J (2000) Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 10:393–406PubMed

73.

Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Lebeoulleux S, Schlumberger M (2003) Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 88:2070–2075

74.

Shah JP (1990) Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. Am J Surg 160:405–409PubMed

75.

Shaha AR, Loree TR, Shah JP (1994) Intermediate-risk group for differentiated carcinoma of thyroid. Surgery 116:1036–1041PubMed

76.

Shaha AR, Loree TR, Shah JP (1995) Prognostic factors and risk groups analysis in follicular carcinoma of the thyroid. Surgery 118:1131–1138PubMed

77.

Shaha AR, Shah JP, Loree TR (1997) Low-risk differentiated thyroid cancer: the need for selective treatment. Ann J Surg Oncol 4:328–333

78.

Shermann SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T, Maxon HR (1998) Prospective multicenter study of thyroid carcinoma treatment. Cancer 83:1012–1021CrossRefPubMed

79.

Simon D, Koehrle J, Reiners C, Boerner AR, Schmutzler C, Mainz K, Goretzki PE, Roeher HD (1998) Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 22:569–574PubMed

80.

Simpson WJ, McKinney SE, Carruthers JS, Gospodarowicz MK, Sutcliffe SB, Panzarella T (1987) Papillary and follicular thyroid cancer. Prognostic factors in 1.578 patients. Am J Med 83:479–488

81.

Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A (2001) Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg 25:617–622PubMed

82.

Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A (2004) A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 135:139–148PubMed

83.

Thomusch O, Dralle H (2000) Endokrine Chirurgie und evidenz-basierte Medizin. Die interdisziplinäre Studie beispielhaft für die endokrine Chirurgie. Chirurg 71:635–645PubMed

84.

Udelsman R, Lakatos E, Ladenson P (1996) Optimal surgery for papillary thyroid cancer. World J Surg 20:88–93PubMed

85.

Wada N, Duh QY, Sugino K, Iwasaki H, Kameyama K, Mimura T, Ito K, Takami H, Takanashi Y (2003) Lymph node metastasis from 259 papillary thyroid microcarcinomas. Ann Surg 237:399–407PubMed

86.

Wanebo H, Coburn M, Teates D, Cole B (1998) Total thyroidectomy does not enhance disease control or survival even in high-risk patients with differentiated thyroid cancer. Ann Surg 227:912–921PubMed

87.

Witte J, Goretzki PE, Dieken J, Simon D, Röher HD (2002) Importance of lymph node metastases in follicular thyroid cancer. World J Surg 26:1017–1022PubMed

88.

Wittekind C, Wagner G (1997) TNM-Klassifikation maligner Tumoren, 5. Aufl. Springer, Berlin Heidelberg New York

89.

Wittekind C, Meyer HJ, Bootz F (2002) TNM-Klassifikation maligner Tumoren, 6. Aufl. Springer, Berlin Heidelberg New York

90.

Wittekind Ch, Greene FL, Henson DE, Hutter RVP, Sobin LH (2003) TNM-Supplement 3^rd en. Wiley-Liss, Hoboken, pp 26–30

Titel: Chirurgie der Schilddrüsenkarzinome
Sollten nach Einführung der neuen TNM-Klassifikation die chirurgischen Leitlinien geändert werden?
verfasst von: Prof. Dr. H. Dralle
A. Machens
M. Brauckhoff
J. Ukkat
C. Sekulla
P. Nguyen-Thanh
K. Lorenz
O. Gimm
Publikationsdatum: 01.01.2005
Verlag: Springer-Verlag
Erschienen in: Die Onkologie / Ausgabe 1/2005
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI: https://doi.org/10.1007/s00761-004-0809-x

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Chirurgie der Schilddrüsenkarzinome

Sollten nach Einführung der neuen TNM-Klassifikation die chirurgischen Leitlinien geändert werden?

Zusammenfassung

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2005

Chemotherapie beim Schilddrüsenkarzinom

Algorithmus zum Schilddrüsenkarzinom

Diagnostik des Schilddrüsenkarzinoms

Radiojodtherapie des Schilddrüsenkarzinoms

Interdisziplinäre Kooperation weiter ausgebaut

Epidemiologie des Schilddrüsenkarzinoms

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie